Literatur
-
1
National Nosocomial Infections Surveillance (NNIS) .
System Report, data summary from January 1992 through June 2003, issued August 2003.
Am J Infect Control.
2003;
31
481-498
-
2
Arthur M, Quintiliani R.
Regulation of VanA- and VanB-type glycopeptide resistance in enterococci.
Antimicrob Agents Chemother.
2001;
45
375-381
-
3
Arthur M, Reynolds P, Courvalin P.
Glycopeptide resistance in enterococci.
Trends Microbiol.
1996;
4
401-407
-
4
Avery R, Kalaycio M, Pohlman B. et al .
Early vancomycin-resistant enterococcus (VRE) bacteremia after allogeneic bone marrow transplantation is associated with a rapidly deteriorating clinical course.
Bone Marrow Transplant.
2005;
35
497-499
-
5
Baden L R, Thiemke W, Skolnik A. et al .
Prolonged colonization with vancomycin-resistant Enterococcus faecium in long-term care patients and the significance of „clearance”.
Clin Infect Dis.
2001;
33
1654-1660
-
6
Bhavnani S M, Drake J A, Forrest A. et al .
A nationwide, multicenter, case-control study comparing risk factors, treatment, and outcome for vancomycin-resistant and -susceptible enterococcal bacteremia.
Diagn Microbiol Infect Dis.
2000;
36
145-158
-
7
Bonten M J, Hayden M K, Nathan C. et al .
Epidemiology of colonisation of patients and environment with vancomycin-resistant enterococci.
Lancet.
1996;
348
1615-1619
-
8
Bonten M J, Slaughter S, Ambergen A W. et al .
The role of „colonization pressure” in the spread of vancomycin- resistant enterococci: an important infection control variable.
Arch Intern Med.
1998;
158
1127-1132
-
9
Borneff-Lipp M, Knoll M, Daeschlein G. et al .
Outbreak of vancomycin-resistant enterococci (VRE) in a hematological oncology ward and hygienic preventive measures. A long-term study.
Onkologie.
2005;
28
187-192
-
10
Christiansen K J, Tibbett P A, Beresford W. et al .
Eradication of a large outbreak of a single strain of vanB vancomycin-resistant Enterococcus faecium at a major Australian teaching hospital.
Infect Control Hosp Epidemiol.
2004;
25
384-390
-
11
Clewell D B.
Bacterial sex pheromone-induced plasmid transfer.
Cell.
1993;
73
9-12
-
12
Collins L A, Malanoski G J, Eliopoulos G M, Wennersten C B, Ferraro M J, Moellering R C.
In vitro activity of RP59500, an injectable streptogramin antibiotic, against vancomycin-resistant gram-positive organisms.
Antimicrob Agents Chemother.
1993;
37
598-601
-
13
DiazGranados C A, Jernigan J A.
Impact of vancomycin resistance on mortality among patients with neutropenia and enterococcal bloodstream infection.
J Infect Dis.
2005;
191
588-595
-
14
DiazGranados C A, Zimmer S M, Klein M, Jernigan J A.
Comparison of mortality associated with vancomycin-resistant and vancomycin-susceptible enterococcal bloodstream infections: a meta analysis.
Clin Infect Dis.
2005;
41
327-333
-
15
Donskey C J, Chowdhry T K, Hecker M T. et al .
Effect of antibiotic therapy on the density of vancomycin-resistant enterococci in the stool of colonized patients.
N Engl J Med.
2000;
343
1925-1932
-
16
Dowzicky M, Talbot G H, Feger C, Prokocimer P, Etienne J, Leclercq R.
Characterization of isolates associated with emerging resistance to quinupristin/dalfopristin (Synercid) during a worldwide clinical program.
Diagn Microbiol Infect Dis.
2000;
37
57-62
-
17
Duckro A N, Blom D W, Lyle E A, Weinstein R A, Hayden M K.
Transfer of vancomycin-resistant enterococci via health care worker hands.
Arch Intern Med.
2005;
165
302-307
-
18 EARSS. European Antimicrobial Resistance Surveillance System 2005. http://www.earss.rivm.nl/
-
19
Fridkin S K, Lawton R, Edwards J R, Tenover F C, McGowan J E, Gaynes R P.
Monitoring antimicrobial use and resistance: comparison with a national benchmark on reducing vancomycin use and vancomycin-resistant enterococci.
Emerg Infect Dis.
2002;
8
702-707
-
20 GENARS. German Network for Antimicrobial Resistance Surveillance. http://www.genars.de/data.htm 2004
-
21
Gonzales R D, Schreckenberger P C, Graham M B, Kelkar S, DenBesten K, Quinn J P.
Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid.
Lancet.
2001;
357
1179
-
22
Hayden M K.
Insights into the epidemiology and control of infection with vancomycin- resistant enterococci.
Clin Infect Dis.
2000;
31
1058-1065
-
23 Huenger F, Ruland P, Haefner H. et al .Persistent single VRE strain is responsible for two outbreaks in an ICU. Poster auf dem 15. European Congress of Clinical Microbiology and Infectious Diseases, Kopenhagen 2005
-
24
Jones M E, Draghi D C, Thornsberry C, Karlowsky J A, Sahm D F, Wenzel R P.
Emerging resistance among bacterial pathogens in the intensive care unit - a European and North American Surveillance study (2000 - 2002).
Ann Clin Microbiol Antimicrob.
2004;
3
14
-
25 Kak V, Chow J W. Acquired antibiotic resistance in enterococci. ASM Press, Washington, D.C M. S. Gilmore (ed.), The enterococci: pathogenesis, molecular biology, and antibiotic resistance 2002: 355-383
-
26
Kauffman C A.
Therapeutic and preventative options for the management of vancomycin-resistant enterococcal infections.
J Antimicrob Chemother.
2003;
51
23-30
(Suppl 3)
-
27
Kawalec M, Gniadkowski M, Kedzierska J, Skotnicki A, Fiett J, Hryniewicz W.
Selection of a teicoplanin-resistant Enterococcus faecium mutant during an outbreak caused by vancomycin-resistant enterococci with the vanB phenotype.
J Clin Microbiol.
2001;
39
4274-4282
-
28
Klare I, Witte W.
Zum Auftreten und zur Verbreitung glycopeptidresistenter Enterokokken.
Epidemiol Bulletin.
2005;
17
149-155
-
29
Lautenbach E, Bilker W B, Brennan P J.
Enterococcal bacteremia: risk factors for vancomycin resistance and predictors of mortality.
Infect Control Hosp Epidemiol.
1999;
20
318-323
-
30
Lautenbach E, Schuster M G, Bilker W B, Brennan P J.
The role of chloramphenicol in the treatment of bloodstream infection due to vancomycin-resistant Enterococcus.
Clin Infect Dis.
1998;
27
1259-1265
-
31
Leclercq R, Derlot E, Duval J, Courvalin P.
Plasmid-mediated resistance to vancomycin and teicoplanin in Enterococcus faecium.
N Engl J Med.
1988;
319
157-161
-
32
May A K, Melton S M, McGwin G, Cross J M, Moser S A, Rue L W.
Reduction of vancomycin-resistant enterococcal infections by limitation of broad-spectrum cephalosporin use in a trauma and burn intensive care unit.
Shock.
2000;
14
259-264
-
33
McGowan J E.
Debate-guidelines for control of glycopeptide-resistant enterococci (GRE) have not yet worked.
J Hosp Infect.
2004;
57
281-284
-
34
Mekonen E T, Noskin G A, Hacek D M, Peterson L R.
Successful treatment of persistent bacteremia due to vancomycin-resistant, ampicillin-resistant Enterococcus faecium.
Microb Drug Resist.
1995;
1
249-253
-
35
Moellering R C.
Linezolid: the first oxazolidinone antimicrobial.
Ann Intern Med.
2003;
138
135-142
-
36
Moellering R C, Linden P K, Reinhardt J, Blumberg E A, Bompart F, Talbot G H. Synercid Emergency-Use Study Group .
The efficacy and safety of quinupristin/dalfopristin for the treatment of infections caused by vancomycin-resistant Enterococcus faecium.
J Antimicrob Chemother.
1999;
44
251-261
-
37
Moreno F, Jorgensen J H, Weiner M H.
An old antibiotic for a new multiple-resistant Enterococcus faecium?.
Diagn Microbiol Infect Dis.
1994;
20
41-43
-
38
Murray B E.
Vancomycin-resistant enterococcal infections.
N Engl J Med.
2000;
342
710-721
-
39
Muto C A, Giannetta E T, Durbin L J, Simonton B M, Farr B M.
Cost-effectiveness of perirectal surveillance cultures for controlling vancomycin-resistant Enterococcus.
Infect Control Hosp Epidemiol.
2002;
23
429-435
-
40
Muto C A, Jernigan J A, Ostrowsky B E. et al .
SHEA guideline for preventing nosocomial transmission of multidrug-resistant strains of Staphylococcus aureus and enterococcus.
Infect Control Hosp Epidemiol.
2003;
24
362-386
-
41
Patel R.
Clinical impact of vancomycin-resistant enterococci.
J Antimicrob Chemother.
2003;
51 Suppl 3
iii13-21
-
42 PEG. Paul-Ehrlich-Gesellschaft Resistenzdaten. http://www.p-e-g.org/ag_resistenz/main.htm 2001
-
43
Raad I I, Hanna H A, Hachem R Y. et al .
Clinical-use-associated decrease in susceptibility of vancomycin-resistant Enterococcus faecium to linezolid: a comparison with quinupristin-dalfopristin.
Antimicrob Agents Chemother.
2004;
48
3583-3585
-
44 SARI. Surveillance der Antibiotika-Anwendung und der bakteriellen Resistenzen auf Intensivstationen. http://www.sari-antibiotika.de/allgemei/funk.htm 2005
-
45
Theilacker C, Krueger W A, Kropec A, Huebner J.
Rationale for the development of immunotherapy regimens against enterococcal infections.
Vaccine.
2004;
22
S31-38
(Suppl 1)
-
46 Ullmann A J, Fischer T, Jansen B, Hube C. Early Cessation of a Vancomycin-Resistant Enterococci (VRE) Outbreak in a Hematology-Oncology Department after Implementation of an Enhanced Infection Control Intervention. A Single Center Experience. Poster auf dem 46. AHS Annual Meeting, San Diego 2004
-
47
Vergis E N, Hayden M K, Chow J W. et al .
Determinants of vancomycin resistance and mortality rates in enterococcal bacteremia: a prospective multicenter study.
Ann Intern Med.
2001;
135
484-492
-
48
Weinstein M P, Mirrett S, Kannangara S. et al .
Multicenter evaluation of use of penicillin and ampicillin as surrogates for in vitro testing of susceptibility of enterococci to imipenem.
J Clin Microbiol.
2004;
42
3747-3751
-
49
Whitman M S, Pitsakis P G, Zausner A. et al .
Antibiotic treatment of experimental endocarditis due to vancomycin- and ampicillin-resistant Enterococcus faecium.
Antimicrob Agents Chemother.
1993;
37
2069-2073
-
50
Wisplinghoff H, Bischoff T, Tallent S M, Seifert H, Wenzel R P, Edmond M B.
Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study.
Clin Infect Dis.
2004;
39
309-317
Priv.-Doz. Dr. Johannes A. Hübner
Medizinische Universitätsklinik und Poliklinik, Klinikum der Albert-Ludwigs-Universität
Hugstetter Straße 55
79106 Freiburg
Phone: +49/761/2701819
Fax: +49/761/2701820
Email: info@if-freiburg.de
